Join to View Full Profile
401 W Greenlawn AveLansing, MI 48910
Phone+1 517-975-9500
Fax+1 517-975-9511
Dr. Conley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 1986 - 1987- University of MarylandFellowship, Hematology and Medical Oncology, 1984 - 1986
Greater Baltimore Medical CenterResidency, Internal Medicine, 1981 - 1984
Graduate HospitalResidency, Surgery, 1979 - 1981
Michigan State University College of Human MedicineClass of 1979
Certifications & Licensure
MI State Medical License 1980 - 2027
MD State Medical License 1981 - 2016
PA State Medical License 1980 - 1981
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2000 Jun 01
- Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment Start of enrollment: 2014 Sep 24
Publications & Presentations
PubMed
- 1 citationsSurvey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptio...Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, Lisa M McShane, Louis M Staudt
Translational Oncology. 2022-11-01 - 6 citationsCorrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: ...Komal Jhaveri, X. V. Wang, Vicky Makker, Shiuh-Wen Luoh, Edith P. Mitchell
Annals of Oncology. 2021-06-04 - 22 citationsDifferential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell
Clinical Cancer Research. 2021-06-01
Journal Articles
- Effect of Capivasertib in Patients with an AKT1 E17K-Mutated TumorKevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Press Mentions
Researchers Look to Effectively Treat Patients with Cancer by Studying Exceptional RespondersMay 31st, 2017
Next-Generation Sequencing Assay Validated Across Labs, Tumor TypesMay 12th, 2017
Transition to Gene-Based Cancer Treatment May Not Be SimpleJune 2nd, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
